Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/151059
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFernández Campos, Francisco-
dc.contributor.authorClares Naveros, Beatriz-
dc.contributor.authorRodríguez Lagunas, María José-
dc.contributor.authorJáuregui Pallarés, Olga-
dc.contributor.authorCasals i Ribes, Isidre-
dc.contributor.authorCalpena Campmany, Ana Cristina-
dc.date.accessioned2020-02-24T11:56:04Z-
dc.date.available2020-02-24T11:56:04Z-
dc.date.issued2019-08-21-
dc.identifier.issn1999-4923-
dc.identifier.urihttp://hdl.handle.net/2445/151059-
dc.description.abstractRhinosinusitis is a prevalent disorder with a severe impact on the health-related quality of life. Saponins of Cyclamen europaeum exert a clinically proven curative effect on rhinosinusitis symptoms when instilled into the nasal cavity, however, more extensive preclinical assessment is required to better characterize the efficacy of this botanical extract. This work evaluates the potential use of a natural freeze-dried extract of C. europaeum given as topical nasal administration. Permeation experiment on porcine nasal mucosa was performed with Franz diffusion cells. Experiments in rabbits were performed to test for any toxicological, hematological, biochemical or histological evidence of systemic action. No theoretical levels of saponins were found in the receptor chamber of Franz diffusion cells. Hematological data did not show significant differences between control and experimental animals (p > 0.05). Histological studies also showed that enhanced secretory activity in response to intranasal administration was not accompanied by any visible signs of injury. An examination of the brain, lungs, liver, kidneys, spleen, and gastrointestinal organs did not reveal any abnormality. The absence of mucosal permeation of saponins and negligible probability of C. europaeum saponins absorption in the course of a therapeutic application was demonstrated.-
dc.format.extent12 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11090426-
dc.relation.ispartofPharmaceutics, 2019, vol. 11, num. 9, p. 426-
dc.relation.urihttps://doi.org/10.3390/pharmaceutics11090426-
dc.rightscc-by (c) Fernández Campos, Francisco et al., 2019-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationFormes farmacèutiques-
dc.subject.classificationMalalties del nas-
dc.subject.classificationDrogues-
dc.subject.otherPharmaceutical dosage forms-
dc.subject.otherNose diseases-
dc.subject.otherDrugs of abuse-
dc.titleEx-Vivo and In-Vivo Assessment of Cyclamen europaeum Extract After Nasal Administration-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec691106-
dc.date.updated2020-02-24T11:56:04Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid31438642-
Appears in Collections:Articles publicats en revistes (Bioquímica i Fisiologia)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
691106.pdf2.31 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons